Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview | 10 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics under Development by Companies | 11 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Products under Development by Companies | 15 | 2 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Companies Involved in Therapeutics Development | 17 | 12 |
| Adverum Biotechnologies, Inc. | 17 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 18 | 1 |
| BioCryst Pharmaceuticals, Inc. | 19 | 1 |
| Cevec Pharmaceuticals GmbH | 20 | 1 |
| CSL Limited | 21 | 1 |
| Global Blood Therapeutics, Inc. | 22 | 1 |
| iBio, Inc. | 23 | 1 |
| Ionis Pharmaceuticals, Inc. | 24 | 1 |
| Pharming Group N.V. | 25 | 1 |
| ProMetic Life Sciences Inc. | 26 | 1 |
| Ra Pharmaceuticals, Inc. | 27 | 1 |
| Shire Plc | 28 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Therapeutics Assessment | 29 | 9 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Target | 30 | 2 |
| Assessment by Mechanism of Action | 32 | 2 |
| Assessment by Route of Administration | 34 | 2 |
| Assessment by Molecule Type | 36 | 2 |
| Drug Profiles | 38 | 30 |
| ANN-002 - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| ARCF-12 - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| avoralstat - Drug Profile | 40 | 1 |
| Product Description | 40 | 1 |
| Mechanism of Action | 40 | 1 |
| R&D Progress | 40 | 1 |
| BCX-7353 - Drug Profile | 41 | 1 |
| Product Description | 41 | 1 |
| Mechanism of Action | 41 | 1 |
| R&D Progress | 41 | 1 |
| BEL-0215 - Drug Profile | 42 | 1 |
| Product Description | 42 | 1 |
| Mechanism of Action | 42 | 1 |
| R&D Progress | 42 | 1 |
| C1 esterase inhibitor (human) - Drug Profile | 43 | 1 |
| Product Description | 43 | 1 |
| Mechanism of Action | 43 | 1 |
| R&D Progress | 43 | 3 |
| C1 esterase inhibitor (human) - Drug Profile | 46 | 1 |
| Product Description | 46 | 1 |
| Mechanism of Action | 46 | 1 |
| R&D Progress | 46 | 2 |
| C1 esterase inhibitor (human) - Drug Profile | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| R&D Progress | 48 | 1 |
| C1 esterase inhibitor (recombinant) - Drug Profile | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| R&D Progress | 49 | 5 |
| C1 esterase inhibitor (recombinant) - Drug Profile | 54 | 1 |
| Product Description | 54 | 1 |
| Mechanism of Action | 54 | 1 |
| R&D Progress | 54 | 1 |
| CSL-312 - Drug Profile | 55 | 1 |
| Product Description | 55 | 1 |
| Mechanism of Action | 55 | 1 |
| R&D Progress | 55 | 1 |
| GBT-18713 - Drug Profile | 56 | 1 |
| Product Description | 56 | 1 |
| Mechanism of Action | 56 | 1 |
| R&D Progress | 56 | 1 |
| icatibant acetate - Drug Profile | 57 | 1 |
| Product Description | 57 | 1 |
| Mechanism of Action | 57 | 1 |
| R&D Progress | 57 | 2 |
| IONIS-PKKRx - Drug Profile | 59 | 1 |
| Product Description | 59 | 1 |
| Mechanism of Action | 59 | 1 |
| R&D Progress | 59 | 1 |
| lanadelumab - Drug Profile | 60 | 1 |
| Product Description | 60 | 1 |
| Mechanism of Action | 60 | 1 |
| R&D Progress | 60 | 2 |
| Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile | 62 | 1 |
| Product Description | 62 | 1 |
| Mechanism of Action | 62 | 1 |
| R&D Progress | 62 | 1 |
| SHP-623 - Drug Profile | 63 | 1 |
| Product Description | 63 | 1 |
| Mechanism of Action | 63 | 1 |
| R&D Progress | 63 | 1 |
| Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile | 64 | 1 |
| Product Description | 64 | 1 |
| Mechanism of Action | 64 | 1 |
| R&D Progress | 64 | 2 |
| Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile | 66 | 1 |
| Product Description | 66 | 1 |
| Mechanism of Action | 66 | 1 |
| R&D Progress | 66 | 1 |
| Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile | 67 | 1 |
| Product Description | 67 | 1 |
| Mechanism of Action | 67 | 1 |
| R&D Progress | 67 | 1 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Recent Pipeline Updates | 68 | 18 |
| Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Product Development Milestones | 86 | 7 |
| Featured News &Press Releases | 86 | 1 |
| May 19, 2016: KalVista Pharmaceuticals to Support Global Conference Focused on Hereditary Angioedema | 86 | 1 |
| Apr 07, 2016: Pharming Announces Adoption By The European Commission Of The CHMP Recommendation To Change The Terms Of The Marketing Authorisation For Ruconest | 86 | 1 |
| Mar 23, 2016: CINRYZE (C1 inhibitor [human]) now available in Canada | 87 | 1 |
| Feb 26, 2016: Pharming Announces Positive CHMP Opinion To Change The Terms Of The Marketing Authorisation For Ruconest | 87 | 1 |
| Feb 09, 2016: Pharming And Cytobioteck Announce Extension Of Distribution Agreement For Ruconest | 88 | 1 |
| Feb 08, 2016: BioCryst Announces Results From OPuS-2 | 88 | 1 |
| Jan 06, 2016: Pharming Announces Completion Of Patient Enrolment In Clinical Study Of Ruconest For Prophylaxis Of Hereditary Angioedema | 89 | 1 |
| Dec 21, 2015: Pharming And Hyupjin Announce Receipt Of The South Korean Marketing Authorisation For Ruconest | 90 | 1 |
| Dec 07, 2015: European Medicines Agency Reaffirms Important Health Benefits and Safety of RUCONEST for Patients With Hereditary Angio-edema | 90 | 1 |
| Nov 09, 2015: Dyax Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology Annual Meeting | 91 | 2 |
| Appendix | 93 | 2 |
| Methodology | 93 | 1 |
| Coverage | 93 | 1 |
| Secondary Research | 93 | 1 |
| Primary Research | 93 | 1 |
| Expert Panel Validation | 93 | 1 |
| Contact Us | 93 | 1 |
| Disclaimer | 94 | 1 |